Tuesday January 28, 2020

Biogen shares plunge after Alzheimer’s drug setback

Biotech giant halts late-stage trials as results disappoint

22nd March, 2019
2
Pic: Getty

Shares in Biogen plummeted yesterday after the biotechnology giant said that its experimental Alzheimer’s drug was unlikely to be effective and that it was halting its research, in another setback to efforts to find a therapy for the neurodegenerative ailment.

Shares dropped by as much as 29 per cent in heavy trading, knocking about $18 billion off the company’s market value and marking its biggest intraday stock drop since 2008.

The US-based company said...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Related Stories

Martin warns Taoiseach that his earlier remarks could ‘undermine’ case for action

Aiden Corkery | 2 months ago

Robbie Fox, the man behind Renards and the Pink Elephant, reflects on the recent closure of his D4 eatery Belluccis and the future of hospitality in a changing city

Róisín Burke | 2 months ago

The party is down to 24 per cent, completely wiping out the gains it had made in the previous Sunday Business Post/Red C poll last month

Michael Brennan | 3 months ago